1. Home
  2. MDGL vs BIO Comparison

MDGL vs BIO Comparison

Compare MDGL & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • BIO
  • Stock Information
  • Founded
  • MDGL 2011
  • BIO 1952
  • Country
  • MDGL United States
  • BIO United States
  • Employees
  • MDGL N/A
  • BIO N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • BIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • MDGL Health Care
  • BIO Industrials
  • Exchange
  • MDGL Nasdaq
  • BIO Nasdaq
  • Market Cap
  • MDGL 6.8B
  • BIO 6.2B
  • IPO Year
  • MDGL N/A
  • BIO N/A
  • Fundamental
  • Price
  • MDGL $275.26
  • BIO $226.40
  • Analyst Decision
  • MDGL Strong Buy
  • BIO Strong Buy
  • Analyst Count
  • MDGL 10
  • BIO 4
  • Target Price
  • MDGL $420.63
  • BIO $330.50
  • AVG Volume (30 Days)
  • MDGL 335.5K
  • BIO 374.2K
  • Earning Date
  • MDGL 05-01-2025
  • BIO 07-31-2025
  • Dividend Yield
  • MDGL N/A
  • BIO N/A
  • EPS Growth
  • MDGL N/A
  • BIO N/A
  • EPS
  • MDGL N/A
  • BIO N/A
  • Revenue
  • MDGL $317,383,000.00
  • BIO $2,541,100,000.00
  • Revenue This Year
  • MDGL $285.43
  • BIO N/A
  • Revenue Next Year
  • MDGL $63.77
  • BIO $3.69
  • P/E Ratio
  • MDGL N/A
  • BIO N/A
  • Revenue Growth
  • MDGL N/A
  • BIO N/A
  • 52 Week Low
  • MDGL $200.63
  • BIO $215.38
  • 52 Week High
  • MDGL $377.46
  • BIO $387.99
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 38.56
  • BIO 41.49
  • Support Level
  • MDGL $265.39
  • BIO $220.31
  • Resistance Level
  • MDGL $275.54
  • BIO $233.28
  • Average True Range (ATR)
  • MDGL 11.39
  • BIO 8.26
  • MACD
  • MDGL -1.08
  • BIO -1.40
  • Stochastic Oscillator
  • MDGL 24.12
  • BIO 16.29

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: